Global Small Molecule Contract Development and Manufacturing Organization (CDMO) Growth Opportunities
Emerging Pharmaceuticals and Highly Potent Complex Molecules Creating Future Growth Potential
13-Sep-2021
North America
Market Research
This study presents Frost & Sullivan’s overall market and segment-wise revenue forecasts of the global small molecule contract development and manufacturing organization (CDMO) industry. It highlights key growth opportunities for small molecule CDMOs based on the main evolution in their business models and strategic approaches as well as those of pharmaceutical sponsors. The study segments the market into two categories based on product type: Active pharmaceutical ingredients (API) manufacturing (API/drug substance) and finished dosage form (FDF) manufacturing (FDF/drug product). API is further segmented into innovator and generic APIs, while FDF is segmented into oral, semi-solid/liquid, and injectable forms. The market forecasts in this report are for 2020–2026, capturing key market developments such as capacity expansions, mergers, acquisitions, and expanding service offerings that are set to affect the overall small molecule CDMO market growth.
Other discussions in the study include:
• The impact of strategic imperatives on the industry
• Growth drivers and restraints
• Comprehensive insights on the competitive landscape
• Revenue share estimates of top market participants
• Strategic analysis of market developments in service offerings and business models
• Growth opportunities for small molecule CDMOs
Author: Surbhi Gupta
Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top Three Strategic Imperatives on the Global Small Molecule Contract Development and Manufacturing Organization (CDMO) Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Scope of Analysis
Market Segmentation by Product Type
Market Segmentation by Service Type
Key Competitors
Key Growth Metrics
Growth Drivers for the Small Molecule CDMO Market
Growth Restraints for the Small Molecule CDMO Market
Forecast Framework—Market Sizing
Forecast Methodology
Forecast Assumptions and Considerations
Revenue Forecast
Revenue Forecast Analysis
Revenue Forecast by Product Type
Revenue Forecast Analysis by Product Type
Revenue Forecast by Region
Revenue Forecast Analysis by Region
Major Reshoring Initiatives for Pharmaceutical Manufacturing
Revenue Split by Service Type
Revenue Split Analysis by Service Type
Competitive Environment
Market Share, Total Pharmaceutical CDMO Market
Small Molecule Market Outlook—Key Segment Share
Comparison between Small Molecules and Biologics Approvals
Expanding CDMO Value Chain—Comprehensive End-to-end Offering for Small Molecules and Biologics
CDMO Business Model Evolution—Transactional to Strategic Partnerships
Key Growth Trends Shaping the Small Molecule CDMO Industry
Key Consolidation and Expansion Steps in the Small Molecule CDMO Industry
Key Expansion Initiatives by Small Molecule CDMOs
Key Growth Metrics, Small Molecule CDMO Market—API
Revenue Forecast, Small Molecule CDMO Market—API
Revenue Forecast by Product Type, Small Molecule CDMO Market—API
Revenue Forecast Analysis by Product Type, Small Molecule CDMO Market—API
Key Growth Metrics, Small Molecule CDMO Market—FDF
Revenue Forecast, Small Molecule CDMO Market—FDF
Revenue Forecast by Product Type, Small Molecule CDMO Market—FDF
Revenue Forecast Analysis by Product Type, Small Molecule CDMO Market—FDF
Revenue Forecast Analysis by Product Type, Small Molecule CDMO Market—FDF (continued)
Growth Opportunity 1—Capacity Expansion in the US and Europe for Reshoring and Near-shoring Manufacturing
Growth Opportunity 1—Capacity Expansion in the US and Europe for Reshoring and Near-shoring Manufacturing (continued)
Growth Opportunity 2—Phase-appropriate Manufacturing Services for High-potency Drugs
Growth Opportunity 2—Phase-appropriate Manufacturing Services (continued)
Growth Opportunity 2—Phase-appropriate Manufacturing Services for High-potency Drugs (continued)
Growth Opportunity 3—Focus on Small/Emerging Biopharmaceutical Companies to Develop Innovative Small Molecules
Growth Opportunity 3—Focus on Small/Emerging Biopharmaceutical Companies to Develop Innovative Small Molecules (continued)
Growth Opportunity 4—Integrated Drug–Device Combination Products Services for New and Existing Drugs
Growth Opportunity 4—Integrated Drug–Device Combination Products Services for New and Existing Drugs (continued)
Your Next Steps
Why Frost, Why Now?
List of Exhibits
List of Exhibits (continued)
Legal Disclaimer
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
Deliverable Type | Market Research |
---|---|
No Index | No |
Podcast | No |
Predecessor | MEF6 |
Author | Surbhi Gupta |
Industries | Healthcare |
WIP Number | PBE8-01-00-00-00 |
Is Prebook | No |
GPS Codes | 9600-B1,9825-B1,9A06-B1,9571-B1,99BF-B1,99C0-B1,99C1-B1,99CB-B1,9568-B1,9611-B1 |